Neurofibroma
MONDO:0016755An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.
Also known as: neurofibroma, neurofibroma (WHO grade I), neurofibroma, benign, NFIB
1516 clinical trials for this condition and its sub-types, 17 tagged with Neurofibroma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neurofibroma
-
Neurofibrosarcoma 33 trials
-
Plexiform neurofibroma 29 trials
-
Atypical neurofibroma 4 trials
-
Pacinian tumor 0 trials
-
Cellular neurofibroma 0 trials
-
Epithelioid neurofibroma 0 trials
-
Mediastinum neurofibroma 0 trials
-
Neurofibroma of gallbladder 0 trials
-
Neurofibroma of spinal cord 0 trials
-
Neurofibroma of the esophagus 0 trials
-
Neurofibroma of the heart 0 trials
-
Light-Activated cream could slow growth of NF1 skin tumors
Disease control Stopped earlyThis trial tests whether a light-activated cream (Levulan Kerastick) followed by red light therapy can slow the growth of benign skin tumors called neurofibromas in people with neurofibromatosis type 1 (NF1). About 30 participants aged 14 and older with superficial tumors on the …
Phase 2 • Sponsor: Donald Basel • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Real-World study tracks Selumetinib's impact on NF1 tumors in children
Disease control Stopped earlyThis study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on tre…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC